Alto Neuroscience, Inc. (ANRO)
CIK 1999480 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 39.2M shares as of Aug 7, 2026 (10-Q).⊙
Cash runway
Self-funding
generates cash
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Additional K2 Warrants | 168,363 | not tagged | — | — |
| New K2 Warrant | 134,691 | not tagged | — | — |
| K2 Warrant | 35,773 | $3.71 | — | — |
| Two Thousand Twenty Five Pre Funded Warrants | not tagged | $0.0001 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 12, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Balance-sheet fair value of warrants: $0 as of Dec 31, 2024.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Amended Loan Agreement | $75.0M | $15.0M | $3.71 | — | ~20.2M sh |
| Grant Agreement | $11.7M | — | not tagged | — | — |
| Loan and Security Agreement | not tagged | — | $4.83 | — | — |
If every note above converted at its tagged price: ~20.2M new shares on 39.2M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 12, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 39.2M | Aug 7, 2026 |
| + Additional K2 Warrants (if exercised) | 168,363 | Jun 30, 2026 |
| + New K2 Warrant (if exercised) | 134,691 | Jun 30, 2026 |
| + K2 Warrant (if exercised) | 35,773 | Feb 29, 2024 |
| + Amended Loan Agreement (if fully converted) | 20.2M | Jan 13, 2025 |
| Fully diluted estimate | 59.8M | +52.4% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $240.1Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 2 executed · 2 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full ANRO workspace
Free to use. No account, no card.